35.08 USD
↘ 1.74 (4.73%)AT CLOSE (11:59 AM EDT)
vTv Therapeutics Inc. Class A Common Stock
VTVTNASDAQ • USD
34.78
↘ 0.30 (0.86%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
34.78
↘ 0.30 (0.86%)
Market: CLOSED
vTv Therapeutics Inc. Class A Common Stock (VTVT) is currently trading at $35.08. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. VTVT is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Jun 26, 2026.
Open?$33.21
High?$38.50
Low?$33.21
Prev. Close?$36.82
Volume?94.2K
Avg. Volume?50.2K
VWAP?$35.66
Rel. Volume?1.88x
Bid / Ask
Bid?$14.05 × 1.0K
Ask?$38.55 × 600
Spread?$24.50
Midpoint?$26.30
Valuation & Ratios
Market Cap?138.2M
Shares Out?3.9M
Float?1.6M
Float %?40.4%
P/E Ratio?61.35
P/B Ratio?1.54
EPS?$0.57
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Employees
26
Market Cap
145.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-07-30
Address
3980 PREMIER DR
HIGH POINT, NC 27265
Phone: 336-841-0300
HIGH POINT, NC 27265
Phone: 336-841-0300
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?40
Piotroski F-Score?0/9Weak
Altman Z-Score?6.46Safe
Confidence?40%Low
Short InterestElevated
Short % of Float?9.95%Elevated
Short Interest?158.5K
Days to Cover?4.7
Free Float1.6M
Avg Daily Volume33.8K
Settlement Date2026-06-15
Financial Health
Current Ratio?14.36Strong
Quick Ratio?14.36Strong
Cash Ratio?14.25Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score80/100
P/E?61.4PRICEY▾
Peers100
S&P9
P/B?1.54CHEAP▾
Peers100
S&P86
P/S?3.75FAIR▾
Peers100
S&P41
P/FCF?N/A▾
EV/EBITDA?-12.6CHEAP▾
S&P97
EV/Sales?1.09CHEAP▾
Peers100
S&P90
Returns & Efficiency
ROE?2.5%WEAK▾
Peers50
S&P17
ROA?2.3%WEAK▾
Peers50
S&P22
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$40.1M
Fundamentals ratios updated end of day